Tiziana Life Sciences CEO Ivor Elrifi buys 321,423 shares, raising his stake to 4.79 million
Tiziana Life Sciences announced that its chief executive, Ivor Elrifi, purchased 321,423 common shares of the company on NASDAQ at $1.00 per share.
The transaction brings Elrifi’s total ownership to 4,793,684 shares, reflecting a significant personal investment in the biotech firm.
Tiziana is developing intranasal foralumab, a fully human anti‑CD3 monoclonal antibody being studied for secondary progressive multiple sclerosis and other neuroinflammatory conditions.
The company highlighted that early data from an expanded access program show disease stability or improvement in all 14 patients treated so far, and a Phase 2a trial is ongoing.
This writeup was produced by pharmadog from original reporting by globenewswire health.
Original headline: “Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer”
read at globenewswire health ↗
comments(0)
5-min edit window · permanent after that